Navigation Links
Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

ion to treat pain, nausea, vomiting, and even malnutrition. Gastroparesis represents a significant unmet medical need as Propulsid(TM) (cisapride), the most widely used product for treating this disorder was removed from the U.S. market in 2000 due to significant cardiovascular adverse effects.

Tranzyme earlier reported that TZP-101 demonstrated excellent tolerability and safety, as well as a desirable pharmacokinetic profile in healthy subjects in two Phase I clinical studies. The Company plans to initiate full Phase II development of TZP-101 for both POI and severe gastroparesis in 3Q 2007. In addition to the ongoing clinical testing of TZP-101 (an intravenous drug), Tranzyme is developing a new oral ghrelin agonist, TZP-102. Tranzyme expects to initiate Phase I clinical testing of TZP-102 in the first quarter of 2008 for the treatment of mild to moderate chronic gastroparesis.

"The Company is making great progress in the development of TZP-101," said Dr. Vipin Garg, President & CEO of Tranzyme Pharma. "Tranzyme's novel ghrelin agonists (TZP-101 and TZP-102) are promising breakthrough drugs with huge commercial potential. Most prokinetic agents under development and on the market act on predominantly central nervous system receptor targets that are also found in the GI tract. Many show potentially serious CNS side effects. Our small molecule ghrelin agonists target a receptor that is more directly involved with regulating gastrointestinal motility."

About Gastroparesis

Gastroparesis results from dysfunction of the nerves of the stomach, leading to postprandial fullness, bloating, early satiety, nausea and vomiting. The three most common etiologies of gastroparesis are diabetes (an estimated 30% of gastroparesis patients), unknown etiology (36%), and post-surgical causes (13%). The prevalence rate of gastroparesis is especially high among diabetic patients, as up to 50% of diabetics worldwide are reported to suffer from gastroparesis
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:9/2/2015)... -- Demers Ambulances is proud to announce it has signed ... the states of Mississippi , ... "This will enable Demers to effectively meet the ... Vice-President for Demers Ambulances. "Emergency Equipment Professionals has three service ... Alabama , giving them a strategic advantage. Local ...
(Date:9/2/2015)... Sept. 2, 2015  Boca Raton Regional Hospital,s ... begun performing ultra-minimally invasive left atrial appendage ligation ... such as Coumadin, Xarelto or Effient. Dr. Cartledge, ... Hospital, is one of a select group of ... two microscopic incisions in order to seal off ...
(Date:9/2/2015)... 2, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at the Rodman & Renshaw 17th Annual ... at 9:35 a.m. ET on Thursday, September 10, 2015. ... public via live audio webcast which can be accessed by ... at http://www.aethlonmedical.com . The webcast will be archived for ...
Breaking Medicine Technology:Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... a developer of Healthcare Technology Networks ("HTN") designed to ... today announces the launch of its proprietary Opioid Management ... United States Bone & Joint Decade , ... suffering from musculoskeletal disease filled 1.6 billion prescriptions. While ...
... SPRING, Md., April 6, 2012 Sunpeaks Ventures, ... "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution ... has entered into a sponsorship agreement ("Agreement") with a ... Clotamin, including advertising, media, and promotional elements. The Agreement ...
Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 3
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... MN (PRWEB) , ... September 02, 2015 , ... ... commercializing products for the upper extremity surgical market, announced today that more than ... for trigger releases in the hand. Plus, nearly 70 of these procedures ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be the deadliest of ... ovarian cancer in her lifetime is approximately 1 in 75. This year it is ... 14,000 will die. , There is no test to detect ovarian cancer. A ...
(Date:9/2/2015)... ... ... “ G-Hold ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... while reducing the likelihood of it dropping. , Tablets like the iPad and Samsung ...
(Date:9/2/2015)... ... September 02, 2015 , ... Please join the world renowned ... which was established by the Foundation in 2007 with the help of Massachusetts ... more research remains our top priority,” commented Christine Buckley, Executive Director of the ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2
... ,Renovis, Inc. (Nasdaq: RNVS ), a biopharmaceutical ... for major medical needs in the areas of,neurological ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... Trade Commission,requesting additional information with regard to the ...
... a lifetime, researchers say, , , THURSDAY, April 3 (HealthDay News) ... victims of maltreatment in 2006 during their first year of ... their first week of life, federal officials reported Thursday. ... risk for nonfatal maltreatment of children less than 1 year ...
... scientists are the first to observe in living cells a ... of the four building blocks that comprise DNA. Also ... replication. The findings, which will be published in the ... to new cancer treatments that prevent cancer cells from replicating ...
... of health care information to,patients for disease management, ... Today URAC called,for public comment on revisions ... accreditation programs. URAC is seeking input from any,interested ... organizations and health plans. The deadline for public,comment ...
... 2008 ... WHO/ WHAT: "Iron Andy" Holder, an Ironman Arizona competitor who was ... this Sunday,s triathlon to encourage others who have chronic ... condition and to live without limits., ...
... 3, 2008 -- A study led by researchers at Memorial ... a particular type of molecule to promote metastasis -- the ... 90 percent of all cancer-related deaths. The study is published ... work examines how cells in the body communicate with each ...
Cached Medicine News:Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 2Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 3Health News:Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3Health News:Enzyme complex could be key to new cancer treatments 2Health News:URAC Releases Draft Standards for Public Input for Nine Health Care Management Accreditation Programs 2Health News:Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Competes in Ironman Arizona in Tempe 2Health News:Researchers learn how signaling molecule orchestrates breast cancer's spread 2
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
... is made from MMA/VP material and has a ... is supplied with the base curve and total ... is available in a power range of -30.00DS ... of protective and therapeutic applications including the controlled ...
... soft contact lenses can be used as ... to relieve corneal pain in the treaent ... as bullous keratopathy, corneal erosions, entropion, corneal ... post-surgical conditions resulting from cataract extraction and ...
Cottle-Joseph Double Hook 12 mm wide....
Medicine Products: